PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibody

PT217是Phanes针对DLL3和CD47的第一类双特异性抗体；atezolizumab（TECENTRIQ®）是罗氏的抗PD-L1单克隆抗体

The clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the treatment of small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinomas (EP-NECs)

临床供应协议将重点评估PT217联合atezolizumab治疗小细胞肺癌（SCLC）、大细胞神经内分泌癌（LCNEC）和肺外神经内分泌癌（EP NEC）

PT217 was recently granted Fast Track designation by the FDA for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor

PT217最近被FDA授予快速通道指定，用于治疗广泛期小细胞肺癌（ES-SCLC）患者，无论是否使用检查点抑制剂，铂类化疗后疾病进展

SAN DIEGO, May 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc  (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that it has entered into a clinical supply agreement with Roche to study PT217, its first-in-class bispecific antibody targeting DLL3 and CD47, in combination with Roche's anti-PD-L1 therapy, atezolizumab, in patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinomas (EP-NECs).

圣地亚哥，2024年5月8日/PRNewswire/--Phanes Therapeutics，Inc（Phanes），一家专注于肿瘤创新药物发现和开发的临床阶段生物技术公司，今天宣布，它已经与罗氏公司签订了临床供应协议，研究其针对DLL3和CD47的第一类双特异性抗体PT217，以及罗氏抗PD-L1疗法atezolizumab，用于小细胞肺癌（SCLC），大细胞神经内分泌癌（LCNEC）和肺外神经内分泌癌（EP NEC）患者。

PT217 was granted orphan drug designation (ODD) for the treatment of SCLC by the FDA in 2022, and recently granted Fast Track designation by the agency for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor..

PT217于2022年被FDA授予孤儿药指定（ODD）用于治疗SCLC，最近被FDA授予快速通道指定，用于治疗广泛期小细胞肺癌（ES-SCLC）患者，无论是否使用检查点抑制剂，铂类化疗后疾病进展。。

Phanes is currently enrolling patients in a multi-center Phase I clinical trial of PT217. The Phase I clinical trial (NCT05652686), known as the SKYBRIDGE study, is currently evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of PT217 in patients with advanced or refractory cancers expressing DLL3.

Phanes目前正在招募患者参加PT217的多中心I期临床试验。被称为天桥研究的I期临床试验（NCT05652686）目前正在评估PT217在表达DLL3的晚期或难治性癌症患者中的安全性，耐受性，药代动力学和初步疗效。

The next phase of Phanes' study is investigating the therapeutic potential of PT217 as a combination therapy in SCLC, LCNEC and EP-NECs. The clinical collaboration with Roche will evaluate PT217 in combination with atezolizumab in these patients..

Phanes研究的下一阶段是研究PT217作为SCLC，LCNEC和EP NEC联合治疗的治疗潜力。与罗氏公司的临床合作将评估PT217联合atezolizumab治疗这些患者。。

'Phanes is very excited about partnering with Roche on this novel approach to treat patients with SCLC, LCNEC and EP-NECs,' said Rita Laeufle, MD, PhD, Chief Medical Officer (CMO) of Phanes. 'DLL3 is highly expressed in SCLC, LCNEC and EP-NECs and an important target for treating these cancers. We believe the mechanisms of PT217 and atezolizumab are complementary and the combination has the potential to improve outcomes for patients.

Phanes首席医疗官（CMO）医学博士Rita Laeufle说：“Phanes非常高兴能与罗氏合作，采用这种新方法治疗SCLC、LCNEC和EP NEC患者。”DLL3在SCLC，LCNEC和EP NEC中高度表达，是治疗这些癌症的重要靶点。我们认为PT217和atezolizumab的机制是互补的，这种组合有可能改善患者的预后。

This collaboration marks another milestone for Phanes in fulfilling our vision of developing innovative approaches to treat cancer.'.

这项合作标志着Phanes在实现我们开发创新癌症治疗方法的愿景方面取得了另一个里程碑。

TECENTRIQ® is a registered trademark of Roche.

TECENTRIQ®是罗氏公司的注册商标。

ABOUT PHANES THERAPEUTICS

关于PHANES THERAPEUTICS

Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, PT199, the TWINPEAK study with PT886 and the SKYBRIDGE study with PT217.

Phanes Therapeutics，Inc.是一家临床阶段生物技术公司，专注于肿瘤领域的创新药物发现和开发。目前，它正在进行三项I期临床试验，包括晨星研究及其最佳单克隆抗体（mAb）计划PT199，PT886的TWINPEAK研究和PT217的SKYBRIDGE研究。

Both PT886 and PT217 are first-in-class bispecific antibodies and have been granted orphan drug designation as well as Fast Track designation by the FDA..

PT886和PT217都是一流的双特异性抗体，已被FDA授予孤儿药称号和快速通道称号。。

The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer.

该公司通过利用其专有技术平台PACbody®、SPECpair®和ATACCbody®建立了强大的渠道，以开发新型生物制剂，解决癌症中高度未满足的医疗需求。

For more information about Phanes Therapeutics, please visit www.phanesthera.com

有关Phanes Therapeutics的更多信息，请访问www.phanesthera.com

For business development or media inquiries, please contact bd@phanestx.com or media@phanestx.com, respectively.

有关业务发展或媒体咨询，请联系bd@phanestx.com或media@phanestx.com，分别。

View original content to download multimedia:https://www.prnewswire.com/news-releases/phanes-therapeutics-inc-announces-clinical-supply-agreement-with-roche-to-evaluate-pt217-in-combination-with-an-anti-pd-l1-therapy-302140379.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/phanes-therapeutics-inc-announces-clinical-supply-agreement-with-roche-to-evaluate-pt217-in-combination-with-an-anti-pd-l1-therapy-302140379.html

SOURCE Phanes Therapeutics

来源Phanes Therapeutics